×
About 2,643 results

ALLMedicine™ Cutaneous T-cell Lymphoma Center

Research & Reviews  830 results

Eruptive Seborrheic Keratoses Are Associated With a Co-Occurring Malignancy in the Majo...
https://doi.org/10.1177/12034754211035124
Journal of Cutaneous Medicine and Surgery; Mirali S, Mufti A et. al.

Nov 30th, 2021 - Eruptive seborrheic keratoses (ESK) is a benign skin condition that has been associated with malignant and nonmalignant diseases. We conducted a systematic review of reported cases of ESK to identify and summarize associated comorbidities. MEDLINE...

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

Nov 25th, 2021 - Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which are being developed by the Laboratory of Molecular Biolo...

A computational in silico approach to predict high-risk coding and non-coding SNPs of h...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601573
PloS One; Khan SM, Faisal AM et. al.

Nov 19th, 2021 - PLCG1 gene is responsible for many T-cell lymphoma subtypes, including peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), cutaneous T-cell lymphoma (CTCL), adult T-cell leukemia/lymphoma along with other diseases. Missen...

Patients without cutaneous T-cell lymphoma frequently harbor CD4 T-lymphocytes that lac...
https://doi.org/10.1002/cyto.b.22041
Cytometry. Part B, Clinical Cytometry; Grzywacz B, Yohe S et. al.

Nov 19th, 2021 - Patients without cutaneous T-cell lymphoma frequently harbor CD4 T-lymphocytes that lack CD26 and/or CD7.|2021|Grzywacz B,Yohe S,Shivers P,Linden MA,Courville EL,|

Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides
https://clinicaltrials.gov/ct2/show/NCT03789864

Nov 18th, 2021 - The purpose of this study is to find out if the laser light-based imaging test called Biodynamic imaging (BDI) can correctly predict the response of cutaneous T-cell lymphoma mycosis fungoides cancer to gemcitabine chemotherapy treatment. No untes...

see more →

Guidelines  2 results

Guidelines on the use of extracorporeal photopheresis.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291097
Journal of the European Academy of Dermatology and Venere... Knobler R, Berlin G et. al.

Dec 21st, 2013 - After the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown sig...

Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneo...
https://doi.org/10.1111/j.1365-2141.2011.08651.x
British Journal of Haematology; Dearden CE, Johnson R et. al.

Apr 13th, 2011 - The peripheral T-cell neoplasms are a biologically and clinically heterogeneous group of rare disorders that result from clonal proliferation of mature post-thymic lymphocytes. Natural killer (NK) cell neoplasms are included in this group. The Wor...

see more →

Drugs  24 results see all →

Clinicaltrials.gov  56 results

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
https://clinicaltrials.gov/ct2/show/NCT01087333

Nov 25th, 2021 - Background: Hairy cell leukemia (HCL) is highly responsive to but not curable by standard chemotherapy, and also responds well to investigational agents called recombinant immunotoxins which are being developed by the Laboratory of Molecular Biolo...

Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides
https://clinicaltrials.gov/ct2/show/NCT03789864

Nov 18th, 2021 - The purpose of this study is to find out if the laser light-based imaging test called Biodynamic imaging (BDI) can correctly predict the response of cutaneous T-cell lymphoma mycosis fungoides cancer to gemcitabine chemotherapy treatment. No untes...

Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
https://clinicaltrials.gov/ct2/show/NCT02192021

Nov 15th, 2021 - This study will evaluate a novel approach to the treatment of patches and plaques in the skin of patients diagnosed with cutaneous t-cell lymphoma utilizing a dissolvable microneedle array (MNA) delivery device that is used to directly and specifi...

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
https://clinicaltrials.gov/ct2/show/NCT04652960

Nov 10th, 2021 - PRIMARY OBJECTIVE: I. To determine the recommended phase II dose (RP2D) or maximum tolerated dose (MTD) of the combination of duvelisib with nivolumab in patients with advanced mycosis fungoides/Sezary syndrome (MF/SS). SECONDARY OBJECTIVES: I. To...

A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT01871727

Oct 28th, 2021 - This is a multicenter, open-label, single-arm study of E7777 in participants with recurrent or persistent CTCL. The study consists of an initial Lead-in part (to select recommended dose of E7777 for Main part), followed by the Main part (to test e...

see more →

News  140 results

FDA Expands Brentuximab Vedotin's Hodgkin Lymphoma Label
https://www.onclive.com/view/fda-expands-brentuximab-vedotins-hodgkin-lymphoma-label

Oct 6th, 2021 - Craig H. Moskowitz, MD The FDA has approved the antibody-drug conjugate (ADC) brentuximab vedotin (Adcetris) as a consolidation therapy following autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma at risk of relapse or ...

Targeted PD-1 Therapy Offers Opportunity to Sequence Agents
https://www.onclive.com/view/targeted-pd-1-therapy-offers-opportunity-to-sequence-agents

Oct 6th, 2021 - Jeffrey S. Weber, MD, PhD Director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center and Research Institute, Tampa, FL Drugs that target the programmed death-1 (PD-1) pathway hold considerable promise for the t...

Topical Remetinostat Demonstrates Efficacy, Tolerability in Basal Cell Carcinoma
https://www.onclive.com/view/topical-remetinostat-demonstrates-efficacy-tolerability-in-basal-cell-carcinoma

Sep 1st, 2021 - The topical HDAC inhibitor remetinostat demonstrated favorable tolerability and clinically significant efficacy in reducing disease burden in patients with basal cell carcinoma, according to results from a phase 2 trial (NCT03180528) published in ...

Diffuse pruritus that first appeared 6 months earlier
https://www.mdedge.com/atopic-dermatitis-challenge-center/article/241734/atopic-dermatitis/diffuse-pruritus-first-appeared

Jun 17th, 2021 - This patient has atopic dermatitis (AD), but on the basis of the image and description above, by no means would this be an intuitive diagnosis; the findings are not characteristic of those in younger patients with AD. Further, clinicians might fin.

Topical Histone Deacetylase Inhibitor Reduced BCC Size in Phase 2 Study
https://www.medscape.com/viewarticle/953042

Jun 14th, 2021 - In the first clinical trial of a topical histone deacetylase (HDAC) inhibitor, remetinostat showed clinical efficacy across several basal cell carcinoma (BCC) tumor types, according to research presented at the annual meeting of the Society for In...

see more →

Patient Education  5 results see all →